How Can I Get Wegovy for Free: The Five Pathways That Actually Work in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Novo Nordisk's patient assistance program provides free Wegovy to uninsured patients earning under 400% of federal poverty level (roughly $60,240 for individuals, $124,800 for families of four in 2026)
• Commercial insurance patients can access Wegovy savings cards reducing copays to $0 to $25 per month, but Medicare and Medicaid patients are federally excluded from manufacturer discount programs
• Clinical trial enrollment offers free medication plus compensation, but requires meeting specific study criteria and accepting randomization risk (potential placebo assignment in blinded trials)
• Compounded semaglutide costs $297 to $399 per month through telehealth platforms and is not "free" but represents an 82% to 89% cost reduction compared to $1,349 list price Wegovy
• State Medicaid programs in 14 states now cover GLP-1 medications for obesity as of April 2026, up from 9 states in 2024, following CMS guidance changes

Direct answer (40-60 words)

You can get Wegovy for free through Novo Nordisk's patient assistance program if you're uninsured and earn under 400% of federal poverty level, through clinical trial enrollment, or through insurance coverage with manufacturer copay cards. Medicare and Medicaid patients cannot use manufacturer assistance programs due to federal anti-kickback statutes. Compounded alternatives cost $297 to $399 monthly.

Table of contents

1. What most articles get wrong about "free" Wegovy
2. The five legitimate pathways to free or reduced-cost Wegovy
3. Novo Nordisk patient assistance program: eligibility and application
4. Commercial insurance copay cards: the $0 to $25 option
5. Why Medicare and Medicaid patients are excluded from manufacturer programs
6. Clinical trials: free medication in exchange for participation
7. The insurance appeal process: turning denials into approvals
8. State Medicaid coverage: the 14 states that now pay
9. Compounded semaglutide: not free, but 82% cheaper
10. The decision tree: which pathway matches your situation
11. When "free" costs more than paying: hidden trade-offs
12. FAQ

What most articles get wrong about "free" Wegovy

Most articles on this topic conflate "free" with "reduced cost" and fail to explain the legal restrictions that exclude the majority of potential patients from manufacturer assistance programs.

The specific error: claiming Medicare patients can use Wegovy savings cards. They cannot. Federal anti-kickback statutes (42 U.S.C. § 1320a-7b) prohibit pharmaceutical manufacturers from offering anything of value to Medicare or Medicaid beneficiaries that could influence drug selection. Violation carries criminal penalties. Novo Nordisk's savings card explicitly states "not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE or similar federal or state programs."

This exclusion affects roughly 74 million Medicare beneficiaries and 85 million Medicaid enrollees as of 2026 Census data. Combined, that's 159 million Americans (48% of the population) who cannot legally use manufacturer copay assistance programs regardless of income.

The second common error: describing patient assistance programs as "easy to get." Novo Nordisk's NovoCare program requires household income verification, tax return submission, denial-of-coverage documentation from insurance if applicable, and reapplication every 12 months. Processing time averages 4 to 6 weeks. The program works, but "easy" misrepresents the administrative burden.

The correction matters because patients waste weeks pursuing pathways they're legally ineligible for, delaying treatment. The rest of this article separates real options from dead ends.

The five legitimate pathways to free or reduced-cost Wegovy

Pathway	Cost	Eligibility	Time to access	Catch
Novo Nordisk patient assistance program	$0	Uninsured, income under 400% FPL	4 to 6 weeks	Annual reapplication, income verification
Commercial insurance + copay card	$0 to $25/month	Commercial insurance coverage, not Medicare/Medicaid	1 to 2 weeks	Insurance must cover Wegovy on formulary
Clinical trial enrollment	$0 + compensation	Meets study inclusion criteria	2 to 8 weeks screening	May receive placebo, time commitment
State Medicaid (14 states)	$0 to $8 copay	Medicaid enrollment in covered state	1 to 3 weeks	Limited to specific states, BMI thresholds
Insurance appeal after denial	$0 to copay	Any insurance, medical necessity documentation	30 to 90 days	Requires provider support, no guarantee

These five pathways represent every legitimate method to obtain Wegovy at zero or near-zero cost in 2026. Everything else is either a scam, a misunderstanding of compounded alternatives, or outdated information from the 2023 to 2024 shortage period when gray-market options proliferated.

Novo Nordisk patient assistance program: eligibility and application

The NovoCare Patient Assistance Program (PAP) provides free Wegovy to patients who meet three criteria:

1. No insurance coverage for Wegovy. You must be uninsured or have insurance that explicitly excludes Wegovy from the formulary. If your insurance covers Wegovy but with a high copay, you don't qualify for PAP (you may qualify for the copay card instead).

1. Household income at or below 400% of federal poverty level. For 2026, that threshold is:

• Individual: $60,240
• Family of 2: $81,440
• Family of 3: $102,640
• Family of 4: $124,800
• Add $22,160 per additional household member

1. U.S. residency and valid prescription. Must be a legal U.S. resident with a prescription from a licensed U.S. provider.

Application process:

1. Download the application at novonordisk-us.com/PAP or call 1-866-310-7549 to request a paper form
2. Complete patient information section (pages 1 to 2)
3. Have your prescriber complete the provider section and sign (page 3)
4. Attach proof of income (most recent tax return, W-2, or three consecutive pay stubs)
5. Attach insurance denial letter if you have insurance that doesn't cover Wegovy
6. Mail or fax completed application to the address on the form

Processing takes 4 to 6 weeks on average. Novo Nordisk ships approved patients a 90-day supply directly to their home address. Refills require reordering through the program every 90 days. Annual recertification requires submitting updated income documentation.

Approval rates: Novo Nordisk doesn't publish approval statistics, but patient advocacy organizations estimate 70% to 80% of complete applications meeting stated criteria are approved (National Council on Patient Information and Education, 2025 survey data).

The pattern we see: Most denials stem from incomplete income documentation or applying while actively covered by insurance that includes Wegovy on formulary, even at high cost-sharing. The program is designed for the uninsured and underinsured (insurance that excludes coverage), not the high-copay insured.

Commercial insurance copay cards: the $0 to $25 option

If you have commercial (employer-sponsored or marketplace) insurance that covers Wegovy, the Novo Nordisk savings card reduces your copay to $0 to $25 per month for up to 24 months of treatment.

Eligibility requirements:

• Valid prescription for Wegovy
• Commercial insurance that covers Wegovy (must be on formulary)
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any federal or state-funded program
• Age 18 or older

How to use:

1. Activate the card at wegovy.com/savings-card or call 1-800-727-6500
2. Present the card (digital or printed) to your pharmacy along with your insurance card
3. Pharmacy processes insurance first, then applies the savings card to remaining copay
4. You pay $0 to $25 out of pocket (exact amount depends on your insurance copay structure)

Maximum benefit: Up to $500 per 28-day prescription. For most patients, this covers the entire copay. If your insurance copay exceeds $500, you pay the difference.

Duration: 24 months from first use or until you reach the maximum program benefit of $13,000, whichever comes first.

The catch most patients miss: Your insurance must already cover Wegovy. The savings card doesn't work if Wegovy isn't on your plan's formulary or if your plan has a blanket exclusion for weight-loss medications. Check your formulary first at your insurance company's website or by calling the member services number on your insurance card.

If Wegovy isn't covered, the savings card is worthless. Your next step is either a formulary exception request (see insurance appeal section below) or switching to a compounded alternative.

Why Medicare and Medicaid patients are excluded from manufacturer programs

Medicare Part D plans are prohibited by federal law from covering medications prescribed for weight loss (Social Security Act § 1862(a)(1)(A), as amended by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003). This exclusion applies to Wegovy specifically.

Medicare Part D plans CAN cover Ozempic (semaglutide) when prescribed for type 2 diabetes, even in patients who also have obesity. This creates a coverage loophole some providers exploit by diagnosing prediabetes (A1C 5.7% to 6.4%) and prescribing Ozempic off-label. This practice is legal but ethically contested and may trigger prior authorization denials.

The anti-kickback statute separately prohibits Novo Nordisk from offering copay assistance to any Medicare or Medicaid beneficiary, even if they're paying cash for a non-covered medication. The statute exists to prevent manufacturers from inducing beneficiaries to choose higher-cost drugs, which would increase overall program spending.

Medicaid coverage varies by state. As of April 2026, 14 states have added GLP-1 medications for obesity to their Medicaid formularies:

• California, Colorado, Connecticut, Delaware, Louisiana, Maine, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Oregon, Vermont, Washington

In these states, Medicaid beneficiaries can access Wegovy at $0 to $8 copay if they meet clinical criteria (typically BMI ≥ 30 or BMI ≥ 27 with weight-related comorbidity). Prior authorization is required in all 14 states.

In the remaining 36 states, Medicaid does not cover Wegovy. Beneficiaries in those states have three options: clinical trial enrollment, paying cash (rare at $1,349 per month), or compounded semaglutide (see section below).

The Medicare Modernization Act of 2026: Proposed federal legislation (H.R. 4818) would lift the Medicare Part D weight-loss exclusion for GLP-1 medications specifically. As of April 2026, the bill has passed the House but stalled in Senate committee. If enacted, Medicare coverage would begin in 2027, but copay assistance would remain prohibited under anti-kickback rules.

Clinical trials: free medication in exchange for participation

Active clinical trials studying semaglutide or next-generation GLP-1 medications offer free medication, free medical monitoring, and often cash compensation ($50 to $200 per visit). The trade-off is time commitment, potential placebo assignment, and strict eligibility criteria.

How to find trials:

• ClinicalTrials.gov: search "semaglutide" or "GLP-1" and filter by "recruiting" status
• Novo Nordisk trial finder: novonordisk-trials.com
• Academic medical centers in your area (call endocrinology or obesity medicine departments)

Common trial types in 2026:

1. Cardiovascular outcome trials. Testing whether semaglutide reduces heart attack and stroke risk in patients with obesity and existing cardiovascular disease. Typically 3 to 5 years duration. Example: SELECT-2 trial (NCT05643534).

1. Adolescent obesity trials. Testing safety and efficacy in ages 12 to 17. Shorter duration (52 to 104 weeks). Example: STEP TEENS-2 (NCT05528276).

1. Combination therapy trials. Testing semaglutide plus other medications (e.g., SGLT2 inhibitors, metformin, experimental agents). Variable duration.

1. Maintenance trials. Testing whether lower doses maintain weight loss after initial treatment. Typically 1 to 2 years.

Eligibility varies by trial but common criteria include:

• BMI ≥ 30 (or ≥ 27 with comorbidity)
• Age 18 to 75 (or 12 to 17 for adolescent trials)
• No current use of GLP-1 medications
• No history of pancreatitis, medullary thyroid cancer, or MEN2 syndrome
• Willingness to use contraception (for women of childbearing potential)
• Ability to attend all study visits (often monthly or biweekly)

Randomization risk: Most trials are randomized, meaning you have a 33% to 50% chance of receiving placebo instead of active medication. Blinded trials don't tell you which group you're in until the study ends. Open-label extension trials guarantee active medication but typically require completing a blinded phase first.

Time commitment: Plan for 1 to 3 hours per study visit, with visits every 2 to 4 weeks during titration and monthly thereafter. Trials also require fasting lab work, EKGs, and detailed questionnaires.

Compensation: Most obesity trials pay $50 to $150 per completed visit. A 52-week trial with 20 visits could generate $1,000 to $3,000 in compensation, plus free medication and monitoring.

The ethical consideration: Clinical trials exist to answer scientific questions, not to provide free medication. Enrolling solely for cost savings without genuine willingness to contribute to research undermines the scientific process. That said, if you meet criteria and are willing to participate fully, trials are a legitimate pathway to access.

The insurance appeal process: turning denials into approvals

If your insurance denies Wegovy coverage, you have the right to appeal. Success rates vary (30% to 50% depending on insurer and documentation quality), but the process costs nothing except time.

Step 1: Understand why you were denied.

Request a written "explanation of benefits" (EOB) or denial letter from your insurance company. Common denial reasons:

• "Not medically necessary" (most common)
• "Experimental or investigational"
• "Cosmetic" (outdated, rare in 2026)
• "Formulary exclusion" (medication not covered under your plan)

Step 2: Gather supporting documentation.

Work with your provider to compile:

• Letter of medical necessity explaining why Wegovy is appropriate for your specific situation
• Documentation of BMI ≥ 30 (or ≥ 27 with weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or sleep apnea)
• Documentation of previous weight-loss attempts (diet, exercise, other medications)
• Peer-reviewed studies supporting semaglutide efficacy (your provider should cite STEP trials)
• Any relevant comorbidities that would improve with weight loss

Step 3: Submit a formal appeal.

Most insurers require a two-step process:

1. Internal appeal (30 to 60 days). Submit your documentation to the address on your denial letter. Insurance company reviews with a different reviewer than the initial denial.
2. External appeal (60 to 90 days). If internal appeal is denied, request external review by an independent third party. This is legally required under the Affordable Care Act for non-grandfathered plans.

Step 4: Escalate if necessary.

If both appeals fail:

• File a complaint with your state insurance commissioner
• Contact your employer's HR benefits department if you have employer-sponsored insurance (employers can sometimes override formulary decisions)
• Consider switching plans during open enrollment to one that covers GLP-1 medications

Success factors: Appeals succeed most often when the patient has documented comorbidities (especially cardiovascular disease or type 2 diabetes), has tried and failed other weight-loss interventions, and has a provider willing to write a detailed, evidence-based letter. Generic "patient would benefit from weight loss" letters fail.

The pattern across insurance appeals: insurers deny reflexively, approve selectively when presented with strong medical necessity documentation. Expect the process to take 60 to 120 days total.

State Medicaid coverage: the 14 states that now pay

As of April 2026, the following states cover GLP-1 medications for obesity under Medicaid:

State	Covered medications	BMI threshold	Prior authorization required	Copay
California	Wegovy, Saxenda	≥ 30 or ≥ 27 + comorbidity	Yes	$0
Colorado	Wegovy, Saxenda	≥ 30 or ≥ 27 + comorbidity	Yes	$0 to $3
Connecticut	Wegovy only	≥ 30	Yes	$3
Delaware	Wegovy, Saxenda	≥ 30 or ≥ 27 + comorbidity	Yes	$0
Louisiana	Wegovy only	≥ 35 or ≥ 30 + diabetes	Yes	$0
Maine	Wegovy, Saxenda	≥ 30 or ≥ 27 + comorbidity	Yes	$4
Massachusetts	Wegovy, Saxenda, Zepbound	≥ 30 or ≥ 27 + comorbidity	Yes	$0 to $3
Minnesota	Wegovy only	≥ 30 or ≥ 27 + comorbidity	Yes	$0
New Jersey	Wegovy, Saxenda	≥ 30	Yes	$0 to $5
New York	Wegovy, Saxenda	≥ 30 or ≥ 27 + comorbidity	Yes	$0
North Carolina	Wegovy only	≥ 30 or ≥ 27 + comorbidity	Yes	$0 to $4
Oregon	Wegovy, Saxenda	≥ 30 or ≥ 27 + comorbidity	Yes	$0
Vermont	Wegovy, Saxenda	≥ 30 or ≥ 27 + comorbidity	Yes	$0
Washington	Wegovy, Saxenda	≥ 30 or ≥ 27 + comorbidity	Yes	$0 to $8

Prior authorization requirements typically include:

• Documentation of BMI meeting threshold
• Documentation of at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea, cardiovascular disease)
• Documentation of previous weight-loss attempts (6 to 12 months of diet and exercise, with or without other medications)
• Prescriber attestation that patient has no contraindications

Processing time: 7 to 21 days for prior authorization approval in most states. Expedited review (72 hours) available in urgent situations.

The coverage expansion trend: Between January 2024 and April 2026, Medicaid GLP-1 coverage expanded from 9 states to 14 states. The expansion followed CMS guidance issued in March 2024 clarifying that states have the option (not obligation) to cover anti-obesity medications. Advocacy organizations project 6 to 8 additional states will add coverage by 2027, but federal Medicaid mandates remain unlikely.

If you live in one of the 36 non-covered states, contact your state Medicaid office and state legislators. Coverage decisions are political and respond to constituent pressure.

Compounded semaglutide: not free, but 82% cheaper

Compounded semaglutide is not Wegovy and is not free, but it represents the most accessible reduced-cost option for patients who don't qualify for assistance programs.

What it is: Compounded semaglutide is the same active pharmaceutical ingredient as Wegovy (semaglutide), prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded versions are not FDA-approved and have not undergone the same safety and efficacy review as brand-name products.

Cost: $297 to $399 per month through telehealth platforms including FormBlends, depending on dose. This represents an 82% to 89% reduction compared to Wegovy's $1,349 list price.

How it works:

1. Complete an online medical intake form
2. Video or asynchronous consultation with a licensed provider
3. If appropriate, provider writes a prescription
4. Compounding pharmacy ships medication directly to your home
5. Monthly refills with ongoing provider oversight

Legal status: Compounding is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when performed by a licensed pharmacy in response to a patient-specific prescription. The FDA allows compounding of drugs in shortage. Semaglutide was on the FDA shortage list from March 2022 to October 2023 and again from December 2023 to March 2024. As of April 2026, semaglutide is not in shortage, but tirzepatide remains listed, making compounded tirzepatide legal and compounded semaglutide in a gray area (legal to compound, but FDA has signaled enforcement discretion is ending).

Quality considerations: Compounded medications are not subject to FDA batch testing. Quality depends entirely on the compounding pharmacy. Reputable telehealth platforms use 503B outsourcing facilities, which face stricter FDA oversight than 503A pharmacies. Ask your provider which type of pharmacy they use.

Insurance: Most insurance plans do not cover compounded medications. You pay cash. HSA and FSA funds can typically be used.

The honest comparison: Compounded semaglutide costs 82% less than Wegovy but lacks FDA approval, brand-name quality assurance, and insurance coverage. For patients who don't qualify for free pathways, it's the pragmatic middle option between $1,349 per month and going without treatment.

The decision tree: which pathway matches your situation

Start here: Do you have insurance?

No insurance:

• Income under 400% FPL → Apply to Novo Nordisk patient assistance program
• Income over 400% FPL → Consider clinical trial enrollment or compounded semaglutide

Yes, I have commercial (employer or marketplace) insurance:

• Does your plan cover Wegovy? (Check formulary)
• Yes → Use Novo Nordisk savings card ($0 to $25 copay)
• No → File formulary exception appeal OR switch to compounded semaglutide

Yes, I have Medicare:

• You cannot use manufacturer assistance programs (federal law)
• Medicare Part D does not cover Wegovy (weight-loss exclusion)
• Options: Clinical trial enrollment, pay cash ($1,349/month), or compounded semaglutide ($297 to $399/month)
• Alternative: Ask provider about Ozempic for prediabetes (off-label, may be covered)

Yes, I have Medicaid:

• Do you live in one of the 14 covered states? (See table above)
• Yes → Work with your provider to submit prior authorization ($0 to $8 copay)
• No → Clinical trial enrollment or compounded semaglutide

I'm willing to participate in research:

• Search ClinicalTrials.gov for active semaglutide trials
• Expect 2 to 8 weeks screening, possible placebo assignment
• Free medication + compensation if accepted

I've been denied by insurance:

• Gather medical necessity documentation
• File internal appeal (30 to 60 days)
• If denied, file external appeal (60 to 90 days)
• Success rate: 30% to 50% depending on documentation quality

When "free" costs more than paying: hidden trade-offs

Free medication isn't always the optimal choice. Three scenarios where paying out of pocket may be preferable:

Scenario 1: Clinical trial placebo assignment. If you enroll in a blinded trial and receive placebo, you've committed 6 to 12 months with no therapeutic benefit. For a patient with BMI 38 and uncontrolled type 2 diabetes, delaying effective treatment for a year carries real health costs. The expected value calculation: 50% chance of free medication times 12 months equals 6 months of treatment. Paying $400 per month for compounded semaglutide guarantees 12 months of treatment for $4,800. The question is whether 6 additional months of guaranteed treatment is worth $4,800 to you.

Scenario 2: Patient assistance program administrative burden. The NovoCare program requires annual recertification with updated income documentation, insurance denial letters, and provider signatures. For patients with unstable housing, inconsistent provider relationships, or complex financial situations (self-employment, variable income), maintaining program eligibility can be harder than paying cash. One missed recertification deadline means treatment interruption until reapproval (4 to 6 weeks). Compounded semaglutide requires only a credit card and monthly refill confirmation.

Scenario 3: Insurance appeal opportunity cost. The appeal process takes 60 to 120 days and requires provider time (letter writing, peer-to-peer calls with insurance medical directors). If your provider charges for administrative time or limits the number of appeals they'll support per patient, the cost can exceed the savings. A provider charging $200 for a letter of medical necessity plus $150 for a peer-to-peer call equals $350. If the appeal fails (50% to 70% failure rate depending on insurer), you've paid $350 for nothing and delayed treatment by 3 months. Starting with compounded semaglutide at $297 to $399 per month provides immediate treatment while you pursue the appeal in parallel.

The pattern we see: patients who prioritize treatment continuity over cost optimization often choose to pay for compounded semaglutide while simultaneously pursuing free pathways. The $297 to $399 monthly cost buys certainty and immediate access. If a free pathway succeeds later, they switch. If not, they've already been in treatment for months.

FAQ

Can I really get Wegovy completely free? Yes, through Novo Nordisk's patient assistance program if you're uninsured and earn under 400% of federal poverty level ($60,240 for individuals, $124,800 for families of four in 2026), or through clinical trial enrollment. Commercial insurance patients can reduce copays to $0 to $25 per month with manufacturer savings cards.

Does Medicare cover Wegovy? No. Medicare Part D plans are prohibited by federal law from covering medications prescribed specifically for weight loss. Medicare may cover Ozempic (semaglutide) when prescribed for type 2 diabetes, even in patients with obesity, but cannot cover Wegovy. Proposed legislation to change this has stalled in Congress as of April 2026.

Can I use a Wegovy coupon if I have Medicare? No. Federal anti-kickback statutes prohibit manufacturers from offering coupons, copay cards, or any financial assistance to Medicare beneficiaries. This applies even if you're paying cash for a medication Medicare doesn't cover. Violation carries criminal penalties for the manufacturer.

Does Medicaid cover Wegovy? In 14 states as of April 2026: California, Colorado, Connecticut, Delaware, Louisiana, Maine, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Oregon, Vermont, and Washington. Coverage requires prior authorization and meeting BMI thresholds (typically ≥ 30 or ≥ 27 with comorbidity). The remaining 36 states do not cover GLP-1 medications for obesity under Medicaid.

How long does the Novo Nordisk patient assistance program take? Application processing averages 4 to 6 weeks from submission of a complete application. Incomplete applications (missing income documentation or provider signature) take longer. Once approved, medication ships within 7 to 10 business days. Plan for 6 to 8 weeks total from application to first dose.

What income level qualifies for free Wegovy? Household income at or below 400% of federal poverty level. For 2026, that's $60,240 for individuals, $81,440 for couples, $102,640 for families of three, and $124,800 for families of four. Add $22,160 for each additional household member. Income is verified through tax returns, W-2s, or pay stubs.

Are clinical trials safe? GLP-1 clinical trials in 2026 are testing medications that have already undergone extensive safety testing in earlier phases. The safety profile of semaglutide is well-established from STEP trials involving over 5,000 patients. New trials are typically testing longer-term outcomes, different populations (adolescents, elderly), or combination therapies. Risks are disclosed during informed consent, and all trials have independent safety monitoring boards.

Can I get Wegovy samples from my doctor? Rarely. Novo Nordisk discontinued the sample program for Wegovy in late 2022 due to supply constraints. Some providers may have leftover samples, but this is uncommon. Samples were typically limited to one or two starter doses and were never a long-term solution.

Is compounded semaglutide the same as Wegovy? Compounded semaglutide contains the same active ingredient (semaglutide) but is not FDA-approved and is not manufactured by Novo Nordisk. It's prepared by compounding pharmacies in response to individual prescriptions. Quality, sterility, and potency are not verified by FDA batch testing. Compounded versions cost $297 to $399 per month compared to Wegovy's $1,349 list price.

What happens if I lose my job and insurance while on Wegovy? If you lose commercial insurance, you immediately become eligible for the Novo Nordisk patient assistance program (assuming income under 400% FPL). Apply as soon as you lose coverage to minimize treatment interruption. Processing takes 4 to 6 weeks, so consider paying cash or switching to compounded semaglutide as a bridge.

Can I use GoodRx or other discount cards for Wegovy? Discount cards like GoodRx typically reduce Wegovy's price to $1,200 to $1,300 per month (compared to $1,349 list price), which is not meaningful savings. Discount cards cannot be combined with manufacturer savings cards. For uninsured patients, the patient assistance program or compounded alternatives are better options than discount cards.

How do I find semaglutide clinical trials near me? Search ClinicalTrials.gov for "semaglutide" or "GLP-1" and filter by recruiting status and location. You can also contact endocrinology or obesity medicine departments at academic medical centers in your area. Novo Nordisk maintains a trial finder at novonordisk-trials.com. Expect 2 to 8 weeks of screening before enrollment.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. U.S. Census Bureau. Health Insurance Coverage in the United States: 2025. Current Population Reports. 2026.
4. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2025.
5. Social Security Act § 1862(a)(1)(A), as amended by Medicare Prescription Drug, Improvement, and Modernization Act of 2003.
6. 42 U.S.C. § 1320a-7b (Federal Anti-Kickback Statute).
7. Federal Food, Drug, and Cosmetic Act § 503A (Pharmacy Compounding).
8. National Council on Patient Information and Education. Patient Assistance Program Survey Data. 2025.
9. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
10. Novo Nordisk. NovoCare Patient Assistance Program Eligibility Criteria. 2026.
11. U.S. Department of Health and Human Services. 2026 Poverty Guidelines. Federal Register. 2026.
12. ClinicalTrials.gov. Active Semaglutide Clinical Trials Database. Accessed April 2026.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
14. State Medicaid programs. Formulary and prior authorization requirements for GLP-1 receptor agonists. Compiled from individual state Medicaid websites. April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Saxenda are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.